PM-73G

PM-73G is a cell-permeable, phosphatase-stable phosphopeptide mimic prodrug that selectively targets the Src homology 2 (SH2) domain of Signal Transducer and Activator of Transcription 3 (STAT3). Developed by researchers at the University of Texas MD Anderson Cancer Center, PM-73G inhibits the phosphorylation of STAT3 at Tyr705, thereby preventing its dimerization, nuclear translocation, and subsequent transcriptional activity. In preclinical models, PM-73G has demonstrated significant efficacy in inhibiting tumor growth, angiogenesis, and vasculogenic mimicry, particularly in breast cancer models such as inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC), without inducing significant direct cytotoxicity or apoptosis in vitro at concentrations that fully block STAT3 phosphorylation.